Capsules used in dry powder inhalers (DPIs) must provide good aerosolization and drug delivery. In addition, powders should empty from the capsule shell with minimum retention. Capsule moisture content and the degree of capsule mold pin lubricant have a direct influence on these properties. Controlling the internal lubricant content is essential for good performance. In contrast, lack of control can lead to high surface roughness, which in turn could increase powder adherence in the capsule and decrease aerosolization.

Inhalation-grade, plant-based capsules can provide an excellent option for use with dry powder inhalers. With good mechanical properties, low moisture content compared with gelatin capsules, and a controlled, lubricated surface, these vegetal-origin capsules can provide good powder emptying, drug delivery and aerosolization.

Qualicaps® Europe, S.A.U.
Spain: +34 91 6 63 0 800
qualicaps.com

Local treatment of lung cancer by the inhalation route is an emerging therapeutic area, particularly for early stages of the disease when the cancer is localized in the lung tissue. This article outlines manufacturing and formulation considerations for local treatment of lung cancer by dry powder inhaler. Using spray drying to engineer respirable particles, three case studies demonstrate the broad applicability of this technology to small and large molecules alike. These studies include:

Dry powder gemcitabine with excipient-enhanced growth
Inhaled bevacizumab dry powder reduces tumor burden in NSCLC rat model
Inhalable bevacizumab/small molecule dry powder combination therapies for NSCLC

Looking forward, future clinical trials for local treatment of lung cancer by dry powder inhaler hold great promise for patients of this challenging disease.

In an initial article, the authors provide a brief history of dry powder inhalers including the earliest reference to therapeutic dry powder inhalation that may also be the earliest reference to "engineered particles," dating from 1849, in London. Other examples include the first recognized pharmaceutical dry powder for inhalation, introduced by Abbott Laboratories in the late 1940s. Another landmark was the Spinhaler® from Fisons Limited, which provided increased dosing capacity and addressed the patient's need for coordinated actuation and inhalation. The article also discusses considerations for future development such as formulation, dose storage, moisture protection and metering, de-aggregative processes, counters, the environment, patient considerations and non-respiratory indications. Then, a new interview considers current challenges and opportunities for DPIs, including ways dry powder inhalers (DPIs) might improve patient technique, patient adherence, smart inhalers and delivery of biologics.

Click for information on the following industry event:

Drug Delivery to the Lungs (DDL) 2022

Please visit Inhalation's website to see contact information for multiple industry organizations, many of which present conferences, workshops and other educational events:

inhalationmag.com/industry-organizations

Questions about Inhalation,
contact Vicki L. Schuman, Editor and Publisher at vschuman@inhalationmag.com.

This email was sent to you from inhnews@cscpublish.com. To ensure delivery of these emails in your inbox,
please add both cscpublish.com and inhalationmag.com to your safe senders list.
Privacy Policy • Unsubscribe

Inhalation Magazine • P.O. Box 27092 • Minneapolis, MN 55427 US

© Whipsnade and Loophole LLC 2022